[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Justine's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":504},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,51,85,118,154,178,204,225,245,274,303,330,358,390,418,448,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100567296","phase-1-phase-12-study-of-mirdametinib--vinblastine-for-newly-diagnosedpreviously-untreated-plgg--activation-of-mapk-100567296",false,"NCT06666348","Phase 1\u002F2 Study of Mirdametinib + Vinblastine for Newly Diagnosed\u002FPreviously Untreated PLGG + Activation of MAPK","A Phase 1\u002F2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway","MIRV","Inclusion Criteria:\n\n* Signed written informed consent prior to study participation.\n* Study activities compliance: must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by contrast enhanced MRI.\n* Aged ≥ 2 years to ≤ 25 years when starting mirdametinib.\n* BSA ≥ 0,40m2\n* Diagnosis:\n\nParticipants must have PLGG with NF1 gene mutation (based on clinical NIH criteria, germline NF1 mutation or molecular analysis of the tumor) or PLGG with KIAA1549-BRAF fusion (based on molecular analysis of the tumor) or PLGG with evidence of MAPK pathway alteration with the exception of patients with BRAF V600E mutation (based on molecular analysis of the tumor).\n\n* Tumor tissue is required (at minimum, paraffin-embedded tissue block and additionally fresh frozen tissue \\[if available\\]). Patients with NF1 and Low Grade Glioma (LGG) can still be enrolled without tissue if no surgery or biopsy was conducted.\n* Baseline MRI.\n* Life expectancy greater than 6 months.\n* Lansky\u002FKarnofsky score ≥ 50.\n* Normal organ and marrow function (see study protocol for specifics).\n* Female and male patients of fertile age must agree to use highly effective contraceptive measures.\n* Must be able to ingest by mouth and retain entirely the administered medication. Mirdametinib can not be administered via nasogastric tube or gastrostomy tube.\n\nExclusion Criteria:\n\n* Patients who are receiving other investigational agents.\n* Cardiac: QTcB ≥ 480 msec or an absolute resting left ventricular ejection fraction (LVEF) of ≤ 49%.\n* Patients who have any other malignancy, except if the other primary malignancy is neither currently clinically significant nor requiring active intervention.\n* Tumor with BRAF V600E mutation.\n* Patients who received previous systemic or radiotherapy treatment.\n* Other severe and uncontrollable medical disease\n* Blood pressure higher than 95th percentile for patient's age, height and gender.\n* Increased risk of serious retinopathy and retinal vein occlusion.\n* Known diagnosis of human immunodeficiency virus infection, hepatitis B or C.\n* Previous major surgery within 2 weeks.\n* History of allergic reactions to compounds of similar chemical or biological composition to mirdametinib.\n* Pregnant or breastfeeding.","ALL","2 Years","25 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This is a 3-part open-label study (feasibility phase, treatment phase and follow-up phase) of orally administered mirdametinib in combination with intravenous vinblastine chemotherapy in patients with PLGG with activation of MAPK pathway.\n\nFeasibility Phase:\n\nThe maximum tolerated\u002Frecommended phase 2 dose (MTD\u002FRP2D) of the mirdametinib plus vinblastine combination will be assessed using a modified Rolling-6 design.\n\nTreatment Phase:\n\nPatients will receive mirdametinib twice daily (continuously) at a fixed dose (2mg\u002Fm2 po BID up to 4 mg BID) for a total of 13 cycles (28 days cycle). Weekly intravenous vinblastine at MTD will be given for a total of 17 cycles. If adverse events occur, two dose reductions are allowed.\n\nFollow-up Phase:\n\nFollowing the end of treatment, patients will be scheduled for a follow-up visit every 6 months for 36 months to evaluate PFS, TTP and OS.",[29],"Pediatric Low-grade Glioma",[31,32,33,34,35,36,37],"PLGG","Pediatric PLGG","Pediatric","MAPK","NF1","KIAA1549-BRAF","pediatric low-grade glioma","RECRUITING","2026-06-08",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2026-01-12",{"date":46,"type":22},"2033-04",{"name":48,"class":49},"St. Justine's Hospital","OTHER",8,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100625448","comparison-of-non-invasive-mean-arterial-blood-pressure-measurements-at-the-arm-and-ankle-during-elective-cesarean-delivery-100625448","NCT07422766","Comparison of Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery.","Observational Study Comparing Non-Invasive Mean Arterial Blood Pressure Measurements at the Arm and Ankle During Elective Cesarean Delivery to Facilitate Skin-to-Skin Contact.","Inclusion Criteria:\n\n* Women scheduled for elective cesarean under neuraxial anesthesia at CHU Sainte-Justine.\n* American Society of Anesthesiologists Physical Status I-III\n* Singleton pregnancy\n* Gestation ≥ 35 weeks\n* BMI \\\u003C 40\n* Able to consent in French or English\n\nExclusion Criteria:\n\n* Cesarean planned under general anesthesia.\n* Multiple pregnancy\n* Prematurity \\\u003C 35 weeks gestation\n* Major fetal anomalies\n* Morbid obesity (BMI ≥ 40)\n* Active labor\n* Emergency cesarean\n* Prisoners\n* Peripheral vascular disease requiring medication or treatment\n* Hypertensive diseases requiring medication\n* Inability to place blood pressure cuff on ankle (amputation, dysmorphism, etc.)\n* Complications requiring significant hemodynamic support (transfusions, inotropes, multiple vasopressors, etc.","FEMALE","18 Years",{"count":61,"type":22},110,"1 Day","OBSERVATIONAL","This observational study aims to compare mean arterial pressure measurements obtained using an ankle blood pressure cuff with those obtained using a standard upper-arm cuff in pregnant individuals undergoing elective cesarean delivery under spinal anesthesia. The primary objective is to determine the level of agreement between the two measurement sites.The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDemonstrate that the mean arterial pressure is similar between arm and ankle with the blood pressure cuff\n\nEvery participant will be their own control. (Measurements will be taken at both sites on every participant)",[66,67,68,69],"Pregnancy","Cesarean Delivery","Blood Pressure Measurement in Pregnancy","Skin to Skin Contact",[71,72,73,74,75],"blood pressure","Mean arterial pressure","pregnancy","cesarean","skin to skin","2026-03-23",{"date":78,"type":42},"2026-03-27",{"date":80,"type":42},"2026-02-26",{"date":82,"type":22},"2026-12",{"name":48,"class":49},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":59,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":84},"100410688","validation-of-continuous-monitoring-of-vital-signs-in-children-with-a-connected-patch-100410688","NCT04627766","Validation of Continuous Monitoring of Vital Signs in Children With a Connected Patch","Validation of Continuous Monitoring of Vital Signs in Children With VTPatch Connected Device in the Pediatric Intensive Care Unit","VITALPICU","Inclusion Criteria:\n\n* Children (0 to 18 years old) admitted in St. Justine's Hospital's PICU.\n* PICU monitoring for the next 24 hours\n\nExclusion Criteria:\n\n* Recent cardiac or thoracic surgery\n* Thoracic skin lesion that contraindicates the VT-Patch\n* No parental consent\n* Intermittent presence of one study observer in the patient room is considered inappropriate by the physician or the nurse in charge because of the child's medical condition","0 Years",{"count":95,"type":22},48,[97],"NA","Small connected devices monitoring vital signs do not exist in children although they could be very useful to monitor patients once they have left the pediatric intensive care unit (PICU) in order to early identify patients at risk of PICU readmission.\n\nThe main objective of this study is to assess the accuracy of a connected thoracic patch (VT-Patch) for the continuous monitoring of vital signs in PICU patients.\n\nThis monitoring device will be used to monitor children in PICU for 8 hours and results will be compared to the standard of care in the unit which is the Philips monitoring system.\n\nThe investigators will assess the device's accuracy for the monitoring of 4 vital signs (SpO2, heart rate, respiratory rate and temperature) and perform exploratory assessment of three additional parameters (EKG, blood pressure and movement capture). The skin colour of each participant will be categorized based on Fitzpatrick scale and non-invasive spectroscopic method.",[100],"Vital Signs",[102,103,104,105,106,107,108,109],"Pediatrics","All-in-One","Wireless","Pateint remote monitoring","SpO2","Pulse oximeter","Skin Colour","VT-Patch","2025-12-11",{"date":112,"type":42},"2025-12-18",{"date":114,"type":42},"2025-02-02",{"date":116,"type":22},"2026-12-31",{"name":48,"class":49},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":142,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":84},"100607351","incidence-of-pruritus-using-intrathecal-fentanyl-versus-epidural-fentanyl-to-initiate-labour-analgesia-100607351","NCT07187427","Incidence of Pruritus Using Intrathecal Fentanyl Versus Epidural Fentanyl to Initiate Labour Analgesia.","Randomized Trial Comparing the Injection of Intrathecal Fentanyl Versus Epidural Fentanyl for the Initiation of Labour Analgesia on the Incidence of Pruritis.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Vaginal delivery\n* Gestational age ≥ 37 weeks\n* Requesting neuraxial analgesia\n* French or English language\n\nExclusion Criteria:\n\n* ASA score \\> 3\n* Allergy or contraindication to receiving opioids\u002Flocal anesthesia (morphine or fentanyl)\n* BMI \\> 40 kg\u002Fm²\n* Hepatic or renal failure,\n* Severe preeclampsia and signs of severity according to the criteria of the American College of Obstetricians and Gynecologists\n* Maternal hemorrhage (placental abruption, hepatic subcapsular hematoma,...)\n* Severe scoliosis\n* Biliary cholestasis or polymorphic eruption of pregnancy\n* Inability to provide informed consent, either secondary to mental or physical disability or a significant language barrier (inability to understand English or French)\n* Prior administration of an opioid or opioid misuse",{"count":126,"type":22},80,[97],"The purpose of this study is to investigate the effect of neuraxial analgesia initiation on the incidence of pruritus in laboring women. Specifically, this study aim to compare intrathecal fentanyl with epidural fentanyl in order to determine whether the epidural route is associated with a lower occurrence and severity of pruritus. By clarifying these differences, the research seek to optimize analgesic strategies during labor while minimizing opioid-related side effects",[130,131,132,133,134,135,136,137,138,139,140,141],"Pruritis","Hypotension Drug-Induced","Urinary Retention","Fetal Bradycardia During Labor","Nausea and Vomitting","Satisfaction, Patient","Labor Analgesia","Neuraxial Opioid","Opioid Analgesic Adverse Reaction","Term Labour","Fentanyl Analgesia","Fentanyl Adverse Reaction",[143,144],"neuraxial opioid induced pruritus during labor","Intrathecal fentanyl versus Epidural fentanyl","NOT_YET_RECRUITING","2025-11-20",{"date":148,"type":42},"2025-11-26",{"date":150,"type":22},"2026-01",{"date":152,"type":22},"2027-05",{"name":48,"class":49},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100606259","use-of-vr-for-diagnostic-hysteroscopy-100606259","NCT07173231","Use of VR for Diagnostic Hysteroscopy","Comparisons Between Virtual Reality and Hypno-Virtual Reality for Procedural Pain and Anxiety During a Diagnostic Hysteroscopy: A Pilot Randomized Controlled Trial","VR-HYSTERO","Inclusion Criteria:\n\n* Minimum 18 years old\n* Speak and read French or English\n* Scheduled to undergo a diagnostic hysteroscopy\n\nExclusion Criteria:\n\n* Having a diagnosis of epilepsy\n* Recent ophthalmologic surgery (\\\u003C 1month) or any ophtalmologic problems that could interfere with the patient's ability to use the VR technology",{"count":163,"type":22},45,[97],"Background: Hysteroscopy (HSC) is a minimally invasive gynecological procedure that is considered to be the gold standard for diagnosing and treating intrauterine pathologies. In recent years, its use in outpatient settings for diagnosis has grown significantly due to its efficiency, low complication rate, and good patient acceptability. However, many patients still report significant pain and anxiety during the procedure. Despite advances in instrumentation and technique, pain remains a key reason for procedural failure, often worsened by preprocedural anxiety. While pharmacological strategies can be used to address this issue, they are not always suitable due to lack of effectiveness or feasibility. As a result, non-pharmacological approaches such as virtual reality (VR) and hypnosis are being increasingly explored. VR has shown potential in reducing pain and anxiety during medical procedures, and its combination with hypnosis may offer enhanced benefits, though current evidence is limited.\n\nObjective: This pilot study aims to assess the effectiveness of immersive virtual reality (IVR) and Hypno-VR (HVR) in managing pain and anxiety during diagnostic HSC and to evaluate the feasibility and acceptability of both IVR and HVR interventions in an outpatient clinical setting.\n\nMethods: This pilot randomized controlled trial (RCT) will follow a three-arm parallel design to compare: 1- standard care, 2- IVR + standard care, and 3- HVR + standard care, during diagnostic HSC. A total of 45 participants (15\u002Farm) will be recruited from the CHU Sainte-Justine's gynecology clinic and randomly assigned to one of the three groups. Primary outcomes will concern feasibility and acceptability including satisfaction of both patients and healthcare professionals. Secondary outcomes will assess self-reported pain and anxiety, physiological responses, procedure duration, procedure failure, and conversion rate from the \"no-touch\" vaginoscopy technique to traditional tools like the speculum and tenaculum. Demographic characteristics will also be explored as potential moderators of intervention effectiveness.\n\nResults\u002FConclusion: This pilot study will provide preliminary data on the effects of IVR and HVR on procedural pain and anxiety during diagnostic HSC. It will also assess the feasibility and the acceptability of integrating these interventions into an outpatient setting. The findings will provide essential data in preparation for a larger clinical trial",[167,168,169],"Hysteroscopy","Anxiety","Pain","2025-09-08",{"date":172,"type":42},"2025-09-15",{"date":174,"type":22},"2025-11",{"date":176,"type":22},"2026-03",{"name":48,"class":49},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":84},"100530106","virtual-reality-distraction-for-dental-anxiety-rct-100530106","NCT06182462","Virtual Reality Distraction for Dental Anxiety (RCT)","The Effects of A Virtual Reality Game on Anxiety During Dental Procedures in Children (VR-TOOTH): A Randomized, Controlled Trial Protocol","Inclusion Criteria:\n\n1. Aged 6 to 17 years;\n2. Received the dentist's recommendation to participate;\n3. Required to undergo any dental procedure;\n4. Accompanied by a parent or a legal guardian who can understand, read, and write in either French or English.\n\nExclusion Criteria:\n\n1. Suffer from epilepsy,\n2. Paralysis or paresis of the hand\n3. Has any diagnosed eye disease\u002Fproblem,\n4. Any other conditions preventing them from using virtual reality (VR) (e.g., epidermolysis bullosa).",true,"6 Years","17 Years",{"count":189,"type":22},88,[97],"The aim of this randomized clinical trial is to verify the efficacy of VR immersion over a muted cartoon on a wall-mounted TV to decrease dental fear and anxiety of children undergoing dental procedures. The study also aims to gain insight on the satisfaction of parents and healthcare providers on the use of VR during dental appointments.\n\nMain research question: Does VR immersion compare to a cartoon on a wall-mounted TV is more efficacious to decrease dental fear and anxiety of children requiring dental procedures?\n\nParticipants will be playing through a VR immersive game wearing a eye-tracking VR headset that requires no movement of the head to play, facilitating the dental procedure.\n\nThe investigators will take measures of the stress levels of participants and their parents using a validated stress scale and also by taking salivary samples to verify the levels of a stress biomarker (alpha-amylase).",[193,194,195,196],"Dental Anxiety","Dental Phobia","Dental Trauma","Dental Diseases","2025-08-18",{"date":199,"type":42},"2025-08-24",{"date":201,"type":42},"2023-11-01",{"date":176,"type":22},{"name":48,"class":49},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100530104","virtual-reality-for-pain-management-during-dupilumab-injection-100530104","NCT06182436","Virtual Reality for Pain Management During Dupilumab Injection","Use of Virtual Reality to Improve Pain and Anxiety Management of Children During Dupilumab Injection for Atopic Dermatitis (VR-DERMA)","VR-DERMA","Inclusion Criteria:\n\n1. between the ages of 6 to 17 years old,\n2. suffering from moderate to severe atopic dermatitis and receiving or about to start subcutaneous injections of dupilumab,\n3. in the presence of a consenting parent who can understand, read, and write either French or English.\n\nExclusion Criteria:\n\n1. have a diagnosed cognitive impairment precluding them from playing a virtual reality game,\n2. suffer from epilepsy considering the nature of the intervention,\n3. cannot be in a sitting position during the procedure as the virtual reality game requires an angle of at least 30 degrees for head-tracking.",{"count":213,"type":22},98,[97],"The aim of this within-subject randomized study is to examine the efficacy of a VR immersive game for pain and anxiety management of children during the subcutaneous injection of dupilumab for moderate to severe atopic dermatitis. We will recruit children from 6 to 17 years.\n\nThe main research question is:\n\n1. Does VR immersive game will generate less anxiety and pain than standard procedures, for children receiving dupilumab injection for moderate to severe atopic dermatitis?\n2. Does the occurence of side effects is similar between both study groups?\n\nParticipants will be randomized according to either sequences: VR-Standard care or Standard care-VR. During the VR sequence, participants will be playing the VR immersive game during the injection. During the Standard care sequence participants will not benefit from any pain management but passive distraction tools will be offered (and documented) to children.\n\nThe investigators will take measures of pain and anxiety, using validated scales, before and after the procedures at each sequence.",[217,169,168],"Atopic Dermatitis",{"date":199,"type":42},{"date":220,"type":42},"2024-05-16",{"date":222,"type":22},"2028-01",{"name":48,"class":49},2,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":84},"100530105","virtual-reality-distraction-for-maternal-milk-expression-pilot-100530105","NCT06182449","Virtual Reality Distraction for Maternal Milk Expression (PILOT)","Feasibility, Acceptability and Effects of Virtual Reality Distraction for Management of Stress in Mothers Expressing Their Maternal Milk (VR-MOM)","VR-MOM","Inclusion Criteria:\n\n1. speak and read French or English\n2. have given birth to a premature newborn at 29 weeks or less\n3. minimum 18 years old\n4. have chosen breastfeeding\n5. who are at least in their second week postpartum\n\nExclusion Criteria:\n\n1. Having a mental health problem or a significant cognitive disorder that prevents them from understanding the purpose of the study\n2. Having a diagnosis of epilepsy",{"count":234,"type":22},20,[97],"Background In neonatal intensive care units (NICUs), mothers are encouraged to express their milk using an electric breast pump. This practice is promoted by nurses and neonatologists due to its beneficial outcomes for newborns. Compared to newborns exclusively fed commercial infant formula, preterm newborns fed breast milk (BM) are less likely to suffer from necrotizing enterocolitis and late-onset sepsis. However, the discomfort associated with using an electrical pump may discourage its use, and almost all mothers start expressing their BM after a premature birth but many stop after a few weeks due to fatigue and stress. Therefore, virtual reality (VR), an immersive experience, seems to be an interesting option as it would provide a relaxing environment and distract mothers of newborns in NICU from the stress and discomfort experienced in order to promote breast milk expression.\n\nAim\n\nThe aim of this within-subject, pilot clinical trial is to assess the feasibility, acceptability, and preliminary effects of VR on stress, discomfort, and volume of expressed milk in mothers of preterm newborns.\n\nMethods\n\nDesign:\n\nWithin-subject, randomized pilot clinical trial in which participants are their own control.\n\nSetting and sample:\n\nLevel 3 neonatal intensive care unit (NICU) at a Montreal pediatric teaching university center. Newborns under 29 weeks of age were chose to ensure that newborns would be admitted and remain in the NICU. The objective is to recruit 20 mothers of premature newborns. This will correspond to a total sample of 40 participants as they will be their own control. There will be 50% more mothers recruited (10) to compensate for the usually high attrition or rejection rate for this population, thus a total sample of 30 mothers. Healthcare professionals (nurses and doctors) providing care to participating mothers will be asked to fill a questionnaire on the feasibility of the VR intervention.\n\nRandomization and exposure to the interventions:\n\nThe sequence of exposure to VR will be randomized, not the participants: sequence of 2 days with VR and 2 days without VR. The study will take place over the course of one week. Participating mothers will either be exposed to VR for a minimum of 2 sessions of 30 minutes\u002Fday for two days and the following two days to the control intervention or the opposite.",[168,238,239],"Milk Expression, Breast","Breast Milk Collection",{"date":199,"type":42},{"date":150,"type":22},{"date":243,"type":22},"2027-06",{"name":48,"class":49},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":273},"100555006","low-value-care-and-variation-in-practice-for-children-hospitalized-with-bronchiolitis-100555006","NCT06506474","Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis","Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis - a Multicentric Prospective Observational Study","CareBEST","Inclusion Criteria:\n\n* Children aged \\>28 days to \\\u003C12 months\n* Children admitted to a pediatric inpatient ward with an admission diagnosis of bronchiolitis\n\nExclusion Criteria:\n\n\\- Children previously recruited for the study, either during a previous bronchiolitis admission or for the same incident of bronchiolitis, while admitted to another study site.","28 Days","12 Months",{"count":256,"type":22},3000,"Low-value care is defined as the use of a health service, such as diagnostics and treatments, for which the harms or costs outweigh the benefits. In pediatrics, investigations or treatments can be unpleasant or traumatizing to the child, can prolong the time spent in hospital, and can create a cascade of further futile investigations and treatments. Several of the commonly used diagnostics and treatments in bronchiolitis are considered low-value, making it a great model to study low-value care in pediatrics.\n\nThe purpose of CareBEST is to study the use of 6 low-value healthcare services in children aged 1 to 12 months hospitalized with bronchiolitis, their costs, and measure the variability in practice of these services.\n\nThe main questions this study aims to answer are:\n\n1. How frequently are 6 low-value care health services used in children hospitalized with bronchiolitis? These 6 low-value care health services are: 1) respiratory virus testing; 2) chest x-rays; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.\n\n   * Are there factors that predict the use of these services?\n   * What are the costs of the use of these services?\n2. How much variability is there between different patients, different doctors, and between hospitals in the use of these 6 low-value health services ?\n3. Are differences in use of low-value health services associated with patient and family characteristics (like race and ethnicity, socioeconomic status, language), and do these contribute to disparities in care?\n\nParticipants will have their infant's medical chart reviewed during their hospitalization. They will also have 2 short questionnaires to complete, once during their child's admission to the hospital, and one 30 days later to ask about whether their child required any additional medical care. They will additionally be asked to complete a questionnaire on their perceptions regarding their child's care while hospitalized, including the use of shared-decision making and their understanding of and involvement in the care decisions made.\n\nThis analysis will provide a better understanding of treatment of bronchiolitis in Canada and help in the development of effective interventions to reduce low-value care.",[259],"Bronchiolitis",[261,262,263,264,265],"infants","hospitalization","bronchiolitis","low-value care","observational study","2025-07-18",{"date":268,"type":42},"2025-07-23",{"date":270,"type":42},"2024-02-13",{"date":243,"type":22},{"name":48,"class":49},15,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":59,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":84},"100189057","dynamo-a-tailored-lifestyle-promotion-intervention-among-pediatric-patients-with-cardiometabolic-risk-factors-100189057","NCT01736748","Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors","Implementing Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors","CIRCUIT","Inclusion Criteria:\n\n* children ages 6 to 18 years of age with a BMI \\> 95th percentile for age and sex\n\nExclusion Criteria:\n\n* children with a physical or psychological condition that would impair their ability to participate in physical activity",{"count":283,"type":22},100,[97],"The Dyn@mo lifestyle intervention (CHU Sainte-Justine, Quebec, Canada) targets children and adolescents aged 6 to 17 years old with cardiometabolic risk factors, such as obesity, hypertension, disorders in glucose regulation or dyslipidemia. Its primary goal is to promote physical activity and reduce sedentary time to improve childrens' cardiometabolic profile. To do so, the intervention relies on gathering data on mobility and physical activity using wearable sensors. These data provide a detailed picture of real-life conditions and physical activity levels, improving the health care professional's ability to tailor counseling. The investigators are presently in the implementation phase of this intervention.",[287],"Obese",[289,290,291,292,293,294],"obesity","physical activity","metabolism","environment","obese children, as defined by a body mass index > 95th percentile","for age and sex","2025-05-20",{"date":297,"type":42},"2025-05-25",{"date":299,"type":42},"2012-08",{"date":301,"type":22},"2030-12",{"name":48,"class":49},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":185,"sex":17,"minAge":310,"maxAge":59,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":84},"100288169","phase-2-twice-daily-treatment-with-amoxicillin-for-non-severe-community-acquired-pneumonia-100288169","NCT03031210","Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.","Treatment of Non-severe Community Acquired Pneumonia With Twice Daily Compared to Thrice Daily Regimen- A Non-inferiority Pragmatic Randomized-controlled Trial.","Inclusion Criteria:\n\n* All patients 3 months to 18 years of age attending the pediatric ED and diagnosed with a non-severe pneumonia, will be considered for enrolment. More precisely, the following inclusion criteria will be required:\n\n  1. Presence of respiratory symptoms (cough and\u002For dyspnea)\n  2. Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles)\n  3. Presence of fever\n  4. Positive chest radiography as interpreted by the treating physician\n\nExclusion Criteria:\n\n* Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abcess or pneumatocoele)\n* History of anaphylactic or allergic reaction to penicillin or amoxicillin according to the treating physician.\n* History of a serious nonimmunoglobulin E-mediated reactions (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis) attributed to amoxicilin.\n* Caregiver unable to provide consent (language barrier or lack of caregiver presence)\n* Underlying unstable chronic illness (ie. cystic fibrosis, immune suppression, active tuberculosis, bronchiectasis or active pulmonary malignancies)\n* Persistent\u002Fchronic pneumonia syndromes (with symptoms for \\>2 weeks), suspected by the physician to be caused by atypical pathogens, hospital- acquired pneumonia (been hospitalized within 2 weeks prior to enrolment), aspiration pneumonia or recurrent pneumonias.\n* Any history of receiving amoxicillin within the past month\n* Need hospitalisation for any other reasons (ie. persistent vomiting, severe life-threatening infection such as septicaemia or meningitis requiring intravenous antimicrobial agents)\n* Previous participation in study","3 Months",{"count":312,"type":22},1370,[26,314],"PHASE3","The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).",[317],"Community-acquired Pneumonia",[319,320,321],"Non-severe community-acquired pneumonia","Amoxicillin treatment","Twice daily antibiotic regimen","2025-05-13",{"date":324,"type":42},"2025-05-14",{"date":326,"type":42},"2017-06-11",{"date":328,"type":22},"2027-06-01",{"name":48,"class":49},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":185,"sex":17,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100575877","implementation-of-momentum-spinetm-a-new-3d-imaging-software-for-idiopathic-scoliosis-100575877","NCT06777992","Implementation of Momentum SpineTM: a New 3D Imaging Software for Idiopathic Scoliosis","Inclusion Criteria:\n\n* Children aged between 8 and 14 with a confirmed radiographic diagnosis of Idiopathic Scoliosis who have not undergone spinal nor thoracic surgery.\n\nExclusion Criteria:\n\n* Patients who may be pregnant. Patients with the existence of a second deformity, or any other neuromuscular condition.","8 Years","14 Years",{"count":339,"type":22},142,"Brief Summary\n\nThe goal of this clinical trial is to evaluate the implementation of Momentum Spine™, a new 3D imaging software designed to improve the monitoring and management of idiopathic scoliosis in children aged 8-14 years. Idiopathic scoliosis affects 1-3% of the pediatric population and is currently monitored through hospital visits with radiographic imaging every 4-6 months, which exposes patients to cumulative radiation over time. This study explores whether Momentum Spine™ can provide a safer, more accessible alternative by enabling at-home monitoring using clinical photographs taken on smartphones.\n\nThe primary questions this study seeks to answer are:\n\nCan Momentum Spine™ accurately predict scoliosis progression, including Cobb angle changes, compared to standard radiographic assessments? Can the use of Momentum Spine™ reduce the number of X-rays required and improve the timing of clinical follow-ups? Does the use of Momentum Spine™ affect patient satisfaction, healthcare utilization, and overall quality of life? This study is a prospective, two-arm randomized controlled trial conducted at CHU Sainte-Justine. Participants will be divided into two groups: the control group will receive standard care, which involves regular clinical visits and radiographic evaluations; the intervention group will use Momentum Spine™ at home, alongside standard care.\n\nIntervention Details\n\nParticipants in the intervention group will:\n\nUse the Momentum Spine™ application to capture 3D images of their torso at home every two months. These images will be processed by Momentum Spine™ algorithms to assess curve progression.\n\nParticipants will receive notifications and guidance on performing scans at home, supported by the study team to ensure accuracy.\n\nThe primary outcomes include clinical measures such as changes in Cobb angle at 1 and 2 years, curve progression of more than 5 degrees, whether the main curve reaches 45 degrees, and the need for surgical referral. Secondary outcomes focus on the accuracy, sensitivity, and specificity of Momentum Spine™, as well as patient-reported measures such as health-related quality of life and satisfaction with care, users' acceptability of the software, healthcare services utilization and pathway costs.\n\nThis study also aims to address key challenges in scoliosis care, including reducing radiation exposure, improving follow-up timing to align with growth spurts, and providing equitable access to care for families who may live far from specialty clinics. By validating the performance of Momentum Spine™, this trial has the potential to transform scoliosis management, ensuring safer and more effective care pathways.",[342,343],"Spine Deformity","Idiopathic Scoliosis",[345,346,347,348,349,102],"Idiopathic scoliosis","Screening","Spine deformity","Progression","Non-invasive 3D scans","2025-01-10",{"date":352,"type":42},"2025-01-16",{"date":354,"type":22},"2025-03",{"date":356,"type":22},"2028-12",{"name":48,"class":49},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":185,"sex":17,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":84},"100557400","best-practices-fo-early-diagnosis-of-cerebral-palsy-100557400","NCT06537622","Best Practices Fo Early Diagnosis of Cerebral Palsy","Implementation of Best Practices for Early Diagnosis of Cerebral Palsy (CP) in Very Preterm Infants: a Stepped-wedge Cluster Randomized Controlled Trial (RCT)","CP","Inclusion Criteria:\n\n* Infants born preterm at less than 29 weeks' GA and their parents\n* Admission to a Neonatal Intensive Care Unit (NICU) participating in the Canadian Neonatal Network (CNN).\n\nExclusion Criteria:\n\n* Death prior to first visit in clinic\n* Major congenital malformation and\u002For significant chromosomal defects affecting development beyond preterm birth\n* Child moved outside Canada prior to first visit in clinic.","2 Months","30 Months",{"count":369,"type":22},2000,[97],"In this research, the investigators are using an implementation science approach to enhance the uptake of a clinical practice guideline for earlier diagnosis of cerebral palsy (i.e. what is being implemented) in neonatal follow-up clinics across Canada. This clinical practice guideline should be part of what neonatal follow-up specialists do in their routine clinical work with children born preterm. However, there is a wide variability in practice. The goal of this project is to harmonize practices in the neonatal follow-up community in agreement with international recommendations for earlier diagnosis of cerebral palsy. This research will measure if clinicians are truly following the clinical practice guideline. If not, implementation strategies that address barriers and leverage on facilitators will be deployed for successful uptake of the clinical practice guideline. This research will also assess whether implementation of the clinical practice guideline is associated with better patient outcomes.",[373,374],"Cerebral Palsy","Prematurity",[376,377,378,379,380,381],"Corrected age","very preterm infants","Developmental functioning","Guideline","Diagnosis","Randomized controlled trial","2024-12-13",{"date":384,"type":42},"2024-12-18",{"date":386,"type":22},"2025-02-01",{"date":388,"type":22},"2028-11-01",{"name":48,"class":49},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":405,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":224},"100566169","smoking-cessation-intervention-including-health-navigators-to-address-unmet-social-needs-of-parents-who-smoke-100566169","NCT06651684","Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","A Randomized Controlled Trial of a Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","CanCEASE-2","Inclusion Criteria:\n\n* Parents or legal guardians aged ≥18 years, with child(ren) aged 0-17 years, attending a regular scheduled medical appointment in one of the study sites.\n* Smokers with at least one self-reported social risk as assessed by validated screening questions on the domains employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy.\n* Sufficiently proficient in French or English to understand and complete study questionnaires.\n\nExclusion Criteria:\n\n* Families presenting at the clinic for an urgent medical issue.\n* Parents without at least one social risk.\n* If both parents smoke, only one parent will be eligible to participate.",{"count":399,"type":22},1000,[97],"Background: The goal of this study is to address parental smoking and social adversity, which can present an obstacle for smoking cessation, in order to decrease childhood exposure to second-hand cigarette smoke. To address these factors, this study includes a smoking cessation intervention for parents and legal guardians recruited in pediatric clinics (CanCEASE), as well as the support of a Health Navigator (HN) to work with the participant towards the resolution or mitigation of unmet social needs.\n\nParticipants: The research team will recruit one thousand participants from pediatric outpatient clinics within two healthcare centres in and around the city of Montreal, Canada, over the course of 2.5 years. Eligible persons are parents and legal guardians, of any sex and gender, accompanying children under 18 to their scheduled medical appointments, and who report at least one social risk in selected areas (i.e., employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy). Participants must also be 18 years old or older with sufficient proficiency in French or English to complete the interviews and questionnaires. In households in which both parents smoke, only one will be eligible to participate, but smoking cessation information will be offered to both. Families presenting at the clinic for an urgent medical issue are not eligible to participate.\n\nIntervention: Participants will be divided into control group (care as usual with CanCEASE at the end of the study period) and intervention (CanCEASE + Health navigator). All participants will complete questionnaires at Baseline, 6 and 12 months. The intervention group will receive CanCEASE at the end of each questionnaire. Controls will receive CanCEASE at 12 months. The intervention group will have the possibility to meet with the HNs and will be invited to commit to at least two sessions (i.e.: evaluation and a follow up), with the option to book more time as needed.\n\nAims and hypotheses: Examining how effective the combination of CanCEASE with HN support is in helping parents with unmet social needs quit smoking. Investigators will also examine the effects of the intervention on status of unmet social needs, if the intervention was implemented as planned and well accepted by clinics and participants, and what is the cost of the intervention for each person who quits smoking.",[403,404],"Smoking Cessation","Tobacco Dependence",[406,407,408,409,410],"Smoking cessation","Social risk","Second hand smoke","Health navigator","Unmet social needs","2024-10-21",{"date":413,"type":42},"2024-10-23",{"date":415,"type":22},"2025-03-01",{"date":301,"type":22},{"name":48,"class":49},{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":17,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":224},"100522832","neuron-qi-an-intervention-to-promote-preterm-infants-neurodevelopment-100522832","NCT06087744","NeuroN-QI: An Intervention to Promote Preterm Infants' Neurodevelopment","Effects of a Parent-preterm Proximity and Calm Intervention (NeuroN-QI) on the Neurodevelopment of Preterm Infants: A Randomized Pragmatic Clinical Trial","Inclusion Criteria for preterm infants:\n\n* born between 24 and 33 6\u002F7 weeks GA;\n* ready for SSC\n\nInclusion criteria for mothers and fathers:\n\n* agree to do at least one SSC session\u002Fweek combined with 10 min of auditory stimulation until 36 weeks of GA of their preterm infant;\n* mothers express breast milk for their preterm infants\n\nFor twin births (twin pregnancies), fathers will also be invited to participate in the study, so that both infants can participate in the study.\n\nExclusion criteria for preterm infants:\n\n* congenital anomalies or genetic disorders\n* intraventricular hemorrhage \\> grade II\n* are small for GA defined as birth weight \\\u003C10th percentile\n* on postnatal day 19 (maximum days targeted for study start)\n* are still receiving analgesics, sedatives, paralyzing agents\n* are under mechanical ventilation\n\nExclusion criteria mothers and fathers:\n\n* are aged \\\u003C18 years;\n* have a physical condition that does not allow the SSC\n* abuse illicit substances or alcohol that could influence stress, anxiety and parent- child interactions\n* feed their preterm infant exclusively with commercial infant formula\n* mothers had a breast surgery that could influence their breast milk production\n* do not speak, read or write in French or in English","24 Weeks","34 Weeks",{"count":428,"type":22},124,[97],"NeuroN-QI aims to evaluate the effects of an intervention consisting of periods of: 1) parents\u002Fpreterm infants skin-to-skin contact and auditory stimulation by the parents's voice and 2) calm without manipulation with olfactory stimulation with breast milk in the incubator\u002Fbed both combined with appropriate light and noise levels to promote neurodevelopment preterm infants.",[432],"Neurodevelopmental Disorders",[434,435,436,437,438,439],"NICU","skin to skin contact","neurodevelopment","preterm infants","positive stimulation","environmental control","2024-04-17",{"date":442,"type":42},"2024-04-19",{"date":444,"type":42},"2023-11-23",{"date":446,"type":22},"2027-10",{"name":48,"class":49},{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":17,"minAge":454,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":473},"100242416","prospective-multicenter-evaluation-of-a-new-predictive-model-for-the-progression-of-adolescent-idiopathic-scoliosis-100242416","NCT02434003","Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis","Inclusion Criteria:\n\n* Idiopathic Scoliosis (as diagnosed by the surgeon)\n* Patients above 10 year old at the time of recruitment\n* Spina bifida occulta with no neurological signs and otherwise normal\n* Curves ranging between 11º and 40º of Cobb angle measurement and\n* Risser 0 or 1, as measured on a standing postero-anterior digital radiograph of the spine.\n* All single thoracic, thoraco-lumbar, lumbar, double major and triple major curves will be included in the study.\n\nExclusion Criteria:\n\n* Previous thoracic, pelvis or spine surgery as they may be co-factors in scoliosis initiation,\n* Congenital scoliosis,\n* MRI abnormalities (including \\> 4mm of Syrinx and\u002For Chiari malformation)\n* Syndromic scoliosis (associated with Marfan's or other genetic syndromes),\n* Neuromuscular scoliosis,\n* Developmental delay\n* Spinal asymmetry\n* Symptomatic spondylolisthesis\n* Leg length discrepancy longer than 1 cm.\n* Unable or unwilling to firmly commit to returning for required follow-up visits","10 Years","15 Years",{"count":457,"type":22},1200,"Scoliosis is a three-dimensional deformity affecting the orientation and position of the spine. Locally, the shape of the vertebra is also affected. The most common form is adolescent idiopathic scoliosis (AIS) with a prevalence of 1-3% affecting primarily young adolescent females. AIS can either be treated using a brace and in some cases necessitate surgical correction to prevent progressive deformity. Risk factors for progression include female gender, curve magnitude and location, skeletal maturity and growth velocity. However, these risk factors have been shown to be inconsistent in predicting curve progression. Over the past 6 years, the investigators have developed a predictive model of the final Cobb angle in AIS based on 3D spinal parameters. This analysis was based on a prospective cohort of 195 patients that were enrolled upon their initial visit and followed until maturity. This predictive model has a determination coefficient of 0.702. The proposed new study aims at refining and testing the external validity of this model in a larger cohort. The next step towards using the new model in the clinical setting is to redesign the model and to externally validate the model by measuring the agreement between the new method and the traditional Cobb angle at maturity in a larger multicenter study. The objective of this study is to characterize the risk of scoliosis progression based on local three-dimensional vertebral and pelvic measurements present on initial evaluation. Three-dimensional reconstructions will be derived from stereo-radiographs acquired with a new biplanar low-dose radiographic system installed in all 8 clinical sites (EOS system, EOS-Imaging, Paris). These calibrated radiographs will then be used to reconstruct the vertebrae and intervertebral disks at each level as well as the geometry of the pelvis. A series of local and regional parameters will then be calculated from these 3D reconstructions. Correlation analysis will help determine if intervertebral disk wedging, vertebral wedging, transverse plane rotation or pelvic geometry can be used as early predictors of curve progression in AIS.\n\nIdentifying a new 3D measure of scoliosis associated with rapid curve progression could help predict which curves need early treatment to prevent further progression. The ultimate goal of this research project will be to validate this new predictive model and finally transfer this new predictive tool in the hands of clinicians treating AIS.",[460],"Scoliosis",[462,463,464,465],"3D reconstruction","AIS","Computer models","Spinal Deformity","2024-04-16",{"date":440,"type":42},{"date":469,"type":4},"2014-05",{"date":471,"type":22},"2027-12",{"name":48,"class":49},9,{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":59,"enrollmentInfo":482,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":484,"conditions":485,"keywords":493,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":50},"100525619","outcomes-of-children-after-hospitalization-in-intensive-care-unit-100525619","NCT06124092","Outcomes of Children After Hospitalization in Intensive Care Unit","After Pediatric Critical Illness (APCI)","APCI","Inclusion Criteria:\n\n* Children ≤18yo hospitalized in PICU for ≥96 hours\n\nExclusion Criteria:\n\n1. gestational age \\\u003C37 weeks or age \\>18 years at PICU entry;\n2. admitted for congenital heart surgery (followed in neuro-cardiac clinics in most centers);\n3. anticipated life expectancy \\\u003C1year (e.g., active do not resuscitate status).",{"count":483,"type":22},690,"More than 10,000 children are hospitalized in an PICU every year in Canada. While most of them will survive their PICU hospitalization and their critical illness, some children will not recover to their pre-illness level. Some may develop behavioral, physical, emotional or developmental problems and difficulties at school. All these problems are elements that are part of the Pediatric Post-Intensive Care Syndrome (PICS-p).\n\nIt is important to understand the elements (risk factors) that play a role in the development of PICS-p. In Canada, there is no systematic follow-up for children after they leave the PICU. Understanding what can cause PICS-p (risk factors) and how much PICS-p has an impact on children and their family is very important to the family well-being.",[486,487,488,489,490,491,492,259],"Renal Disease","Liver Diseases","Heart Diseases","Trauma Injury","Sepsis","Septic Shock","Pneumonia",[494,495],"Pediatric Intensive Care Unit","PICU","2023-11-03",{"date":498,"type":42},"2023-11-09",{"date":500,"type":22},"2024-03",{"date":502,"type":22},"2029-03",{"name":48,"class":49},""]